Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.0051 | 0.1928 | 0.4787 |
Leishmania major | hypothetical protein, conserved | 0.0051 | 0.1928 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0051 | 0.1928 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0038 | 0.098 | 0.098 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0063 | 0.2719 | 0.2719 |
Loa Loa (eye worm) | hypothetical protein | 0.0045 | 0.1471 | 0.1322 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.1928 | 0.3251 |
Schistosoma mansoni | hypothetical protein | 0.0167 | 1 | 1 |
Echinococcus multilocularis | geminin | 0.0167 | 1 | 1 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0051 | 0.1928 | 0.5 |
Brugia malayi | Bromodomain containing protein | 0.004 | 0.1153 | 0.2673 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0063 | 0.2719 | 0.2719 |
Brugia malayi | hypothetical protein | 0.0033 | 0.066 | 0.1327 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.1331 | 0.0732 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0051 | 0.1928 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0051 | 0.1928 | 0.5 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0038 | 0.098 | 0.098 |
Loa Loa (eye worm) | hypothetical protein | 0.0074 | 0.3526 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0051 | 0.1928 | 0.5 |
Schistosoma mansoni | bromodomain containing protein | 0.0066 | 0.2981 | 0.2981 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0051 | 0.1928 | 0.5 |
Brugia malayi | Bromodomain containing protein | 0.0079 | 0.3839 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0051 | 0.1928 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0167 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.